Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

167 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis

NCT05366036

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Site #20 Cheonan, Chungcheongnam-do, South Korea
  • Site #15 Ansan, Gyeonggi-do, South Korea
  • Site #08 Bucheon-si, Gyeonggi-do, South Korea
  • Site #09 Goyang-si, Gyeonggi-do, South Korea
View all 20 locations
View Trial Details
Completed

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

NCT04580381

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Department of Neurology, CHU Bobigny-Avicenne Bobigny, France
  • Department of Neurology, CHU de Caen Caen, France
  • Department of Neurology, Percy Military Hospital Clamart, France
  • Department of Neurology, CHU Nice Nice, France
View Trial Details
Completed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02861014

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • St George Hospital Kogarah, New South Wales, New South Wales, Australia
  • Hospital Erasme Brussels, Belgium
  • Cliniques Universitaires St-Luc Brussels, Belgium
  • UZ Antwerpen Edegem, Belgium
View all 163 locations
View Trial Details
Completed

Tecfidera and the Gut Microbiota

NCT02471560

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Research site Drammen, Norway
  • Research site Haukeland, Norway
  • Research Site Lillehammer, Norway
  • Research site Lørenskog, Norway
View Trial Details

Related conditions